Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.

The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.

However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.

Partners Fresenius Kabi and Formycon have laid the groundwork to launch their biosimilar ustekinumab rival to Stelara in Europe and Canada through a settlement agreement with originator J&J.